|
|
|
l |
Home | l | UK Companies | l | Genomics Topics | l | Species with sequenced Genomes | l | Contact |
l |
|
Loading...
| ||||||||||||||
Recent Publications by Oxagen Ltd.: | ![]() | |
| Pharmacologic Profile of OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist That Inhibits Mast Cell-Dependent Activation of T Helper 2 Lymphocytes and Eosinophils.
D prostanoid receptor 2 (DP(2)) [also known as chemoattractant... | Oxagen Ltd, 91 Milton Park, Abingdon, Oxon, OX14 4RY, United Kingdom. | J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. Epub 2011 Nov 21.
DOI Direct Link |
| Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway.
It is now well established that interaction of PGD(2) with chemoattractant... | Oxagen | J Immunol. 2009 Jun 15;182(12):7580-6.
DOI Direct Link |
| Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells.
The mechanisms by which immunologically activated mast cells stimulate the... | Clin Exp Immunol. 2009 Apr;156(1):126-33. Epub 2009 Feb 11.
DOI Direct Link |
|
| Antagonists of the prostaglandin D2 receptor CRTH2.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and... | Pharmacology, Oxagen | Drug News Perspect. 2008 Jul-Aug;21(6):317-22.
DOI Direct Link |
| The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and... | Oxagen Ltd, 91 Milton | Br J Pharmacol. 2008 Mar;153 Suppl 1:S191-9. Epub 2007 Oct 29.
DOI Direct Link |
Oxagen Ltd. Patents: | ![]() |
| US Patent No. | Title |
| 8044088 | 1-acetic acid-indole derivatives with PGD2 antagonist activity |
| 7999119 | Compounds having CRTH2 antagonist activity |
| 7919512 | Compounds having CRTH2 antagonist activity |
| 7750027 | Compounds having CRTH2 antagonist activity |
| 7582672 | Compounds for the treatment of CRTH2-mediated diseases and conditions |